Friday, June 19, 2026

pharma · Thyroid eye disease · Thyroid Eye Disease · VRDN

Viridian Pharma

Viridian Pharma patent portfolio — 3 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

200 Market Street, ELMWOOD PARK, NJ 07407, US HQ
2017 Founded
2 Employees
Public company Type
VRDN · NYSE Ticker
Company details
Intelligence · Patents

Viridian Pharma patents

3 pharmaceutical patents indexed for Viridian Pharma. 0 expire within 24 months.

Viridian Pharma has 3 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12404335

    Compositions and methods for treatment of thyroid eye disease

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12404337

    Compositions, doses, and methods for treatment of thyroid eye disease

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11548951

    Compositions and methods for treatment of thyroid eye disease

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Viridian Pharma have?

3 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Viridian Pharma patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.